Thu, Apr 24, 2014, 1:18 PM EDT - U.S. Markets close in 2 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

The Blackstone Group L.P. Message Board

carolyn_novice 373 posts  |  Last Activity: 29 minutes ago Member since: Feb 3, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Zacks Investment Research - Rates PLUG as BUY

    by seoraffi Mar 18, 2014 9:53 AM
    carolyn_novice carolyn_novice Mar 18, 2014 9:55 AM Flag

    ZACK is always wrong. Blame yourself and not Zack for your losses.

    CN

    Sentiment: Strong Sell

  • Reply to

    Literally going to 5.74. Get out first

    by txrkill64 Mar 18, 2014 9:52 AM
    carolyn_novice carolyn_novice Mar 18, 2014 9:53 AM Flag

    There will be some rally, brokers need more money from traders.

    CN

    Sentiment: Strong Sell

  • Sell and help the shorts.

    Thanks in advance for listening and cutting your losses.

    Sincerely,

    Carolyn Novice

    Sentiment: Strong Sell

  • Reply to

    Albumin-Alzhemer

    by sandpailsandpail Mar 18, 2014 12:18 AM
    carolyn_novice carolyn_novice Mar 18, 2014 12:19 AM Flag

    Thanks.

    Keep us informed.

    Sincerely,
    Carolyn Novice

    Sentiment: Strong Buy

  • George Soros Bought $1.3 Billion Worth of Put Options on the S&P 500
    Submitted by RobHino on Wed, 02/26/2014 - 19:10

    We are not in a recovery. What we are witnessing right now is the creation of a speculative bubble of epic proportions and that bubble is going to burst. We've been saying this for some time now, but when a major player like George Soros, a billionaire investor known for positioning himself on the right side of a risky trade starts actively betting against the U.S. stock market trouble is brewing.

    Soros has recently purchased 1.3 billion dollars worth of put options on the S&P 500. Some have tried to down play this as merely.

    Sincerely,

    Carolyn Novice

  • Reply to

    Bloodbath

    by rationalthought3 Mar 14, 2014 8:36 AM
    carolyn_novice carolyn_novice Mar 17, 2014 9:34 PM Flag

    Traders are very careful, they are afraid of you may be George Soros.

    Good luck!

    Sincerely,

    Carolyn Novice

  • Reply to

    Bloodbath

    by rationalthought3 Mar 14, 2014 8:36 AM
    carolyn_novice carolyn_novice Mar 17, 2014 9:23 PM Flag

    If market goes down on Ukraine and then recovers next day, what happens after that?

    Sincerely,
    Carolyn Novice

  • Reply to

    Wisdom of George Soros BX @ 33.08

    by carolyn_novice Mar 14, 2014 10:41 AM
    carolyn_novice carolyn_novice Mar 17, 2014 9:21 PM Flag

    You did not read properly. Please excuse.

    Sincerely,

    Carolyn Novice

  • Reply to

    Wisdom of George Soros BX @ 33.08

    by carolyn_novice Mar 14, 2014 10:41 AM
    carolyn_novice carolyn_novice Mar 17, 2014 9:20 PM Flag

    I read lately, George Soros has more than billion in puts for unexpected decline. He has international portfolio.

    Please don’t be personal. You can go back to your theme, long-term buy, and when stock goes down buy more.

    I do not have more money to buy more; I have to sell to buy some thing different.

    If you ignore my message you will sleep nicely, and we have to quarrels. It is market, it is up and down, and for every buy some one has to sell. Let it be me.

    Good luck!

    Sincerely,

    Carolyn Novice

  • Reply to

    Wisdom of George Soros BX @ 33.08

    by carolyn_novice Mar 14, 2014 10:41 AM
    carolyn_novice carolyn_novice Mar 17, 2014 9:11 PM Flag

    No.

    I have no desire to end up in the tower of London for providing wrong information.

    Sincerely,

    Carolyn Novice
    I enjoy Cricket match

  • carolyn_novice carolyn_novice Mar 17, 2014 9:07 PM Flag

    angmar2000 Hopefully you got out of PLUG at the right time! You will lose quickly if you are on the wrong side of the hype.
    Sincerely,
    A. M. London

    Thanks, I know what I am doing. There is no need to worry about me. Whenever you find time, do the following:

    Please Google Search the following and also see on YouTube.

    Manias, Panics, and Crashes: A History of Financial Crises By
    Charles P. Kindleberger.

    Sincerely,

    Carolyn Novice

  • carolyn_novice by carolyn_novice Mar 17, 2014 8:53 PM Flag

    mike2915 and sam_0534, kindly, please ignore this message and start a new message for your readers. ……It is doubtful based on below, BX making big progress for next few days; however smart traders can smell and feel the trend. Traders can use this and prove me wrong.

    Fundamentally, BX can come with news tomorrow and BX can do anything. …..But very unlikely. Option behavior says so.

    1. Today volume 33,692 is the lowest for nearly two months.
    2. Why the buyers are on strike?
    3. Will sellers decided to bailout at bid and volume increase on the downside?
    4. Will the volume increase on decline, or on advance, please observe for signal.
    5. There are nearly 225,000 shares related to options exercised by March 28, 2014
    6. Professionals who wrote options (smart money) expects stock will not make a new high.
    7. Based on OBV stock needs to be up for 4 to 5 days in a row.
    8. BX to be up for 4 days in row, it is going to be doubtful based on graph, and over head supply.
    9. Buyers in the range 34.50 – 35.39, offer big resistance.
    10. Today’s volume was low on the up move; BX will consolidate and not expected to make any progress towards new high. Not worth trader’s time and money.

    Unless there is some major news which we do not know, for traders chasing BX at these levels is not recommended.

    Sincerely,

    Carolyn Novice

  • After hours last trade 6.44 ..volume 151,375….5:45pm
    There is lot of volume on option by the floor traders. Which indicates, there will be big selling of PLUG before March 28, 2014

    Let buyer be aware Caveat Emptor.

    Good luck!

    Protect you hard earned money from Goldman Sachs traders with 250,000 annual bonuses.

    Sincerely,

    Carolyn Novice

    Sentiment: Strong Sell

  • carolyn_novice carolyn_novice Mar 17, 2014 4:12 PM Flag

    Brokers are making money, a trap for you.

    Sincerely,

    Carolyn Novice

    Sentiment: Strong Sell

  • Reply to

    I bought PLUG at $3.98 on margin last month

    by ilroyjetson420 Mar 14, 2014 3:27 PM
    carolyn_novice carolyn_novice Mar 17, 2014 4:10 PM Flag

    White lie, stocks under $4.00 are not margin able.

    Please try another story.
    Sincerely,

    Carolyn Novice

    Sentiment: Strong Sell

  • Reply to

    PLUG is a good short stock to trade

    by r2d2cd Mar 17, 2014 3:16 PM
    carolyn_novice carolyn_novice Mar 17, 2014 3:22 PM Flag

    Thanks a million. What took you so long? Please create 5 more IDs and after shorting a few thousand shares, tell everyone. The good future and the stock going to 10..15..20.

    Good luck!

    Sincerely,

    Carolyn Novice

    Sentiment: Strong Sell

  • This impact will wear out soon. Good news is just an excuse for good stocks to move. GRFS needs to consolidate at these levels.

    Among leading stocks, essentially all of the IBD 50 stocks climbed out of Monday's starting gate.

    Spain-based Grifols (GRFS) jumped 5%. The plasma product provider may have gained a boost from Vodafone's (VOD) announced $9.7 billion acquisition of Spanish telecom provider Ono as a vote of confidence on Spain's economy. Grifols shares are rising from support at the 10-week moving average.
    Source: IBD

    Good Luck!

    Sincerely,

    Carolyn Novice

    Sentiment: Strong Buy

  • Reply to

    The New America IBD GRFS 42.40

    by carolyn_novice Mar 17, 2014 12:35 PM
    carolyn_novice carolyn_novice Mar 17, 2014 12:36 PM Flag

    Geographic Expansion
    Meanwhile, Grifols has expanded its blood-separation, or fractionation, plants in Clayton, N.C., and Barcelona. It intends to increase plasma fractionation capacity from 8.5 million liters of plasma per year to 12.5 million by 2016.
    The company also operates plants in Los Angeles, Melville, N.Y., Mexico, Switzerland and Australia.
    In the third quarter, revenue in the U.S. grew 14.3% from the year-ago period. Growth was even faster in Latin America and China. Overall revenue rose 4.4% to 2,046.6 million euros, or around $880 million. (Grifols reports in euros only.)
    In China, demand for the protein albumin, a plasma expander, is particularly strong. China has been importing albumin, used to replenish lost blood or to treat trauma, due to problems with the quality of the nation's supplies, Anderson says.
    "China is a huge growth opportunity for blood-plasma companies," said analyst Andrew. "Some believe that over time China will allow additional (blood proteins) to come in."
    Albumin is part of Grifols' core plasma-protein bioscience division, which accounts for nearly 90% of revenue. Albumin, the fastest growing product in the division, logged growth of more than 24% in the third quarter.
    The firm's earnings are growing much faster than revenue.
    Per-share earnings in ADRs have grown in double digits the last seven quarters. In the third quarter, they jumped 42% to 34 cents. Analysts expect full-year profit of $1.67 a share, up from $1.03 last year.
    They see 2014 earnings rising another 22% to $2.04, according to Thomson Reuters.
    Grifols' two smaller divisions are involved in diagnostics, driven by sales of blood typing cards, and hospital products. The diagnostics unit will become a much larger part of Grifols' business once the Novartis acquisition is completed, taking it from 4% of sales to 20%, Deutsche Bank analysts in Europe estimate.
    But they note that profitability of the Novartis assets has not been disclosed. And a majority of the estimated $100 million in royalty income alone could go away as core patents around hepatitis C testing expire in 2015 and 2016, they added.
    Source IBD
    Sincerely,
    Carolyn Novice

    Sentiment: Strong Buy

  • Reply to

    The New America IBD GRFS 42.40

    by carolyn_novice Mar 17, 2014 12:35 PM
    carolyn_novice carolyn_novice Mar 17, 2014 12:35 PM Flag

    Broader Portfolio
    Talecris expanded Grifols' plasma collection platform to 147 donor centers across the U.S. and gave it new products in immunology, pulmonology, neurology, critical care and hemostasis.
    "A lot of countries want U.S.-sourced plasma. It's believed to be the highest-quality plasma," said Ben Andrew, a William Blair analyst. He adds that Grifols is "extremely well-managed" and has "never had a product recall."
    Grifols was founded in 1940 in Barcelona by CEO Victor Grifols' grandfather, the late scientist Jose Antonio Grifols. The elder Grifols was one of the first to discover how blood plasma can be removed from whole blood without depleting red blood cells. The original lab specialized in tools for clinical analysis and blood transfusions.
    Since the Talecris buyout was completed in June 2011, the company has traded as an American Depositary Receipt in the U.S. Its ADR shares have climbed 168% since, and 32% so far this year.
    Andrew says that Grifols' ADRs trade at more than a 30% discount to shares traded on the Madrid exchange, in part because it's lightly covered by U.S. analysts and management doesn't go out of its way to court Wall Street.
    "It's a little bit of an odd duck, but it's a great odd duck," Andrew said of Grifols' stock in the U.S.
    Way To Grow
    Grifols has kept acquiring. The latest: a $1.7 billion deal to buy Novartis' (NVS) blood testing diagnostics unit, in a transaction expected to close in the first half of 2014.
    Novartis' blood screening portfolio focuses on tests for HIV, hepatitis B and West Nile virus, among other indications. It drew about $750 million in revenue last year.
    "The Novartis acquisition makes Grifols more vertically integrated, since it will basically have all the tests that are necessary to be run on blood samples," said Morningstar's Anderson.
    In 2012, Grifols bought 51% of Araclon Biotech, advancing its research-and-development pipeline in areas outside plasma.
    Araclon, a 2004 spinoff from Spain's University of Zaragoza, is involved in diagnostics and therapies for Alzheimer's disease.
    Grifols has kept expanding outside its core expertise in blood plasma. Earlier this year it bought a 60% interest in Progenika Biopharma, a Spanish diagnostic and prognostic firm that personalizes treatments in genetically complex diseases.
    It also recently took a minority stake in TiGenix, a biotech based in Belgium that develops therapies using stem cells for treating autoimmune and inflammatory diseases, among others. TiGenix's new cellular therapy for repairing knee cartilage is approved for use in Europe.

    Sentiment: Strong Buy

  • carolyn_novice by carolyn_novice Mar 17, 2014 12:35 PM Flag

    Biopharma Grifols Builds In Blood Therapies Worldwide
    By MARILYN ALVA, INVESTOR'S BUSINESS DAILY
    Posted 12/11/2013 05:23 PM ET
    Biopharma plasma firm Grifols isn't letting Spain's financial crisis get it down.
    International expansion is a key component of the Barcelona-based company's growth strategy.
    Though that expansion began in the 1990s, its acquisition of North Carolina-based Talecris Biotherapeutics two years ago marked a turning point for Grifols (GRFS), making it one of the three largest global manufacturers of plasma-based protein biological medicines. The deal was valued at $3.4 billion.
    Blood plasma is Grifols' core area of expertise, though the company has been expanding in areas such as diagnostics and cellular therapies too.
    As CEO Victor Grifols told shareholders earlier this year, Talecris made the 73-year-old firm "a truly global company," with more than 90% of its income generated outside Spain.
    The other two major global players are Illinois-based Baxter International (BAX) and Australia-based CSL Behring, which is publicly traded in Australia.
    Morningstar analyst Karen Anderson says the plasma business is essentially an oligopoly, with Baxter, CSL and Grifols holding a majority of the world market, each with roughly 20% share.
    Sales generated by Grifols within Spain have continued to decline, though at a slower pace than previously, as austerity measures rein in the nation's high debt.

    Sentiment: Strong Buy

BX
32.11-0.050(-0.16%)1:18 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.